TB/Micobactérias Não Tuberculosas
Estudo randomizado | Alta dose de rifampicina com ou sem levofloxacino vs. cuidado padrão na meningite tuberculosa pediátrica.
25 Mar, 2022 | 14:27hNovas diretrizes da OMS sobre o tratamento da tuberculose em crianças e adolescentes.
23 Mar, 2022 | 12:10hConteúdo relacionado: RCT: In children with nonsevere, drug-susceptible tuberculosis, treatment for 4 months is noninferior to treatment for 6 months.
Abordagem baseada em evidências e consenso de especialistas | Escore validado para avaliar a instabilidade da coluna e verificar a indicação cirúrgica na tuberculose espinal ativa.
22 Mar, 2022 | 11:21hEstudo de coorte | Inibidores de TNF aumentam o risco de infecção por micobactéria não tuberculosa em pacientes com artrite reumatoide soropositiva em uma área endêmica para tuberculose micobacteriana.
16 Mar, 2022 | 17:27hRevisão | Infecção cutânea por micobactérias.
14 Mar, 2022 | 13:40hMycobacterial skin infection – Current Opinion in Infectious Diseases
Estudo randomizado | Em crianças com tuberculose não grave e suscetível a medicamentos, o tratamento por 4 meses é não inferior ao tratamento por 6 meses.
10 Mar, 2022 | 15:59hComunicado de imprensa: Treatment length reduced for children with tuberculosis – University College London
Comentário no Twitter
Completing 6 months of treatment for tuberculosis in children is a challenge. In this open-label trial involving 1204 children in sub-Saharan Africa and India, 4 months of antituberculosis therapy was noninferior to 6 months of therapy. https://t.co/zkD4URWMru pic.twitter.com/LFR6ZzTKgs
— NEJM (@NEJM) March 9, 2022
Revisão com imagens | Tuberculose extrapulmonar: um problema antigo, mas que sempre ressurge.
9 Mar, 2022 | 13:27hExtrapulmonary tuberculosıs: an old but resurgent problem – Insights into Imaging
Nova diretriz provisória do CDC recomenda um regime de 4 meses de rifapentina-moxifloxacino para tratamento da tuberculose pulmonar não resistente.
28 Fev, 2022 | 13:41hConteúdos relacionados:
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
WHO Guideline: Screening for Tuberculosis Disease
New WHO Recommendations to Prevent Tuberculosis
CDC Guidelines for the Treatment of Latent Tuberculosis Infection
Guideline: Treatment of Drug-Resistant Tuberculosis
The Lancet Commission: Management of Multidrug-resistant and Incurable Tuberculosis
Regimens to Treat Multidrug-resistant Tuberculosis: Past, Present and Future Perspectives
Guidelines for the Management of TB in Adults Living with HIV
Comentário no Twitter
Clinicians: @CDC_TB released interim guidance on a new regimen to treat #TB disease. Learn more about the 4-month regimen containing rifapentine, moxifloxacin, isoniazid, and pyrazinamide for people with drug-susceptible pulmonary TB disease in the U.S.: https://t.co/eOcR34tYJu pic.twitter.com/EFGMwAwN7c
— MMWR (@CDCMMWR) February 25, 2022
Artigo | Tuberculose em tempos de COVID-19.
15 Fev, 2022 | 11:50hTuberculosis in times of COVID-19 – Journal of Epidemiology & Community Health
Conteúdos relacionados:
Covid-19’s Devastating Effect on Tuberculosis Care — A Path to Recovery.
Global tuberculosis progress reversed by COVID-19 pandemic.
How COVID is derailing the fight against HIV, TB and malaria.
How COVID hurt the fight against other dangerous diseases
World TB Day | Report: COVID-19 Eliminates Twelve Years of Progress Against Tuberculosis
Tuberculosis and Covid-19: Fighting a deadly syndemic